

I. 英文原著・総説・教科書

- (1) Anetai Y, Sumida I, Takahashi Y, Yagi M, Mizuno H, Ota S, Suzuki O, Tamari K, Seo Y, Ogawa K. A concept for classification of optimal breathing pattern for use in radiotherapy tracking, based on respiratory tumor kinematics and minimum jerk analysis. *Med Phys*. 2016;43:3168
- (2) Baek S, Isohashi F, Yamaguchi H, Mabuchi S, Yoshida K, Kotsuma T, Yamazaki H, Tanaka E, Sumida I, Tamari K, Otani K, Seo Y, Suzuki O, Yoshioka Y, Kimura T, Ogawa K. Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer. *Brachytherapy* 2016;15:812-816
- (3) Baek SJ, Sato K, Nishida N, Koseki J, Azuma R, Kawamoto K, Konno M, Hayashi K, Satoh T, Doki Y, Mori M, Ishii H, Ogawa K. MicroRNA miR-374, a potential radiosensitizer for carbon ion beam radiotherapy. *Oncol Rep*. 2016;36:2946-2950.
- (4) Chen AB, Minami K, Raposo JF, Matsuura N, Koizumi M, Yokota H, Ferreira HG. Transient modulation of calcium and parathyroid hormone stimulates bone formation. *Endocrine*. 2016;54:232-240.
- (5) Harada H, Fuji H, Ono A, Kenmotsu H, Naito T, Yamashita H, Asakura H, Nishimura T, Takahashi T, Murayama S. Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. *Cancer Sci*. 2016;107:1018-21
- (6) Inoue T, Widder J, van Dijk LV, Takegawa H, Koizumi M, Takashina M, Usui K, Kurokawa C, Sugimoto S, Saito AI, Sasai K, Van't Veld AA, Langendijk JA, Korevaar EW. Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. 2016;96:661-9
- (7) Ishiyama H, Satoh T, Yorozu A, Saito S, Kataoka M, Hashine K, Nakamura R, Tanji S, Masui K, Okihara K, Ohashi T, Momma T, Aoki M, Miki K, Kato M, Morita M, Katayama N, Nasu Y, Kawanaka T, Fukumori T, Ito F, Shiroki R, Baba H, Inadome A, Yoshioka Y, Takayama H, Hayakawa K. Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy. *J Radiat Res* 2016;57:68-74
- (8) Isohashi F, Mabuchi S, Akino Y, Yoshioka Y, Seo Y, Suzuki O, Tamari K, Yoshino K, Sawada K, Ueda Y, Kobayashi E, Sumida I, Mizuno H, Okubo H, Kimura T, Ogawa K. Dose-volume analysis of predictors for chronic gastrointestinal complications in patients with cervical cancer treated with postoperative concurrent chemotherapy and whole-pelvic radiation therapy. *J Radiat Res* 2016;57:668-676
- (9) Kanayama N, Nishiyama K, Kawaguchi Y, Konishi K, Ogawa K, Suzuki M, Yoshii T, Fujii T, Yoshino K, Teshima T. Selective neck irradiation for supraglottic cancer: focus on Sublevel IIb

- omission. *Jpn J Clin Oncol.* 2016;46:51-6.
- (10) Kawashiro S, Harada H, Katagiri H, Asakura H, Ogawa H, Onoe T, Sumita K, Murayama S, Murata H, Nemoto K, Takahashi M, Nishimura T. Reirradiation of spinal metastases with intensity-modulated radiation therapy: an analysis of 23 patients. *J Radiat Res.* 2016;57:150-6
- (11) Kobayashi S., Gotoh K., Takahashi H., Akita H., Marubashi S., Yamada T., Teshima T., Nishiyama K., Yano M., Ohigashi H., Ishikawa O., Sakon M. Clinicopathological features of surgically-resected biliary tract cancer following chemo-radiation therapy. *Anticancer Research.* 2016;36: 335-42
- (12) Kojima H, Isaka M, Nagata M, Onoe T, Murayama S, Ohde Y. Preoperative Proton Beam Therapy for Thymoma: A Case Report. *Ann Thorac Cardiovasc Surg.* 2016;22:186-8.
- (13) Kurosu K, Sumida I, Mizuno H, Otani Y, Oda M, Isohashi F, Seo Y, Suzuki O, Ogawa K. Curtailing patient-specific IMRT QA procedures from 2D dose error distribution. *J Radiat Res.* 2016;57:258-64
- (14) Kusumoto C., Ohira S., Miyazaki M., Ueda Y., Isono M., Teshima T. Effect of various methods for rectum delineation on relative and absolute dose-volume histograms for prostate IMRT treatment planning. *Med. Dosim.* 2016; 41: 136-41.
- (15) Mabuchi S, Isohashi F, Yokoi T, Takemura M, Yoshino K, Shiki Y, Ito K, Enomoto T, Ogawa K, Kimura T. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. *Gynecol Oncol.* 2016;141:240-6.
- (16) Miyazaki M., Nishiyama K., Ueda Y., Ohira S., Tsujii K., Isono M., Masaoka A., Teshima T. Preliminary analysis of sequential simultaneous integrated boost technique for intensity-modulated radiotherapy for head and neck cancers. *J. Radiat. Res.* 2016;57: 406-11.
- (17) Mizumoto M, Murayama S, Akimoto T, Demizu Y, Fukushima T, Ishida Y, Oshiro Y, Numajiri H, Fuji H, Okumura T, Shirato H, Sakurai H. Proton beam therapy for pediatric malignancies: a retrospective observational multicenter study in Japan. *Cancer Med.* 2016;5:1519-25.
- (18) Murakami S, Verdonschot RG, Kakimoto N, Sumida I, Fujiwara M, Ogawa K, Furukawa S. Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer. *PLoS One.* 2016;11:e0154226.
- (19) Murakami S, Verdonschot RG, Kataoka M, Kakimoto N, Shimamoto H, Kreiborg S. A standardized evaluation of artefacts from metallic compounds during fast MR imaging. *Dentomaxillofac Radiol.* 2016;45:20160094
- (20) Nakahara S, Hanamoto A, Seo Y, Miyaguchi S, Yamamoto Y, Tomiyama Y, Yoshii T, Takenaka Y, Yoshioka Y, Isohashi F, Ogawa K, Inohara H. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced

- nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients. *Jpn J Clin Oncol* 2016;46:903–910
- (21) Nakahara S, Takenaka Y, Ogawa K, Nishiike S, Yamamoto Y, Seo Y, Isohashi F, Suzuki O, Yoshioka Y, Sumida I, Yoshii T, Tomiyama Y, Inohara H. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma. *Int J Clin Oncol* 2016;21:1030–1037
- (22) Noda Y, Kishino M, Sato S, Hirose K, Sakai M, Fukuda Y, Murakami S, Toyosawa S. Galectin-1 expression is associated with tumour immunity and prognosis in gingival squamous cell carcinoma. *J Clin Pathol* 2016
- (23) Nose T, Otani Y, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Shikama N, Kumazaki Y, Takahashi T, Yoshida K, Kotsuma T, Masuda N, Yoden E, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M. A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: clinical results with a median follow-up of 26 months. *Breast Cancer* 2016;23:861–8
- (24) Ohira S, Ueda Y, Nishiyama K, Miyazaki M, Isono M, Tsujii K, Takashina M, Koizumi M, Kawanabe K, Teshima T. Couch height-based patient setup for abdominal radiation therapy. *Med Dosim.* 2016;41:59–63.
- (25) Ohira S, Ueda Y, Hashimoto M, Miyazaki M, Isono M, Kamikaseda H, Masaoka A, Takashina M, Koizumi M, Teshima T. VMAT-SBRT planning based on an average intensity projection for lung tumors located in close proximity to the diaphragm: a phantom and clinical validity study. *J Radiat Res.* 2016;57:91–7.
- (26) Otani K, Teshima T, Ito Y, Kawaguchi Y, Konishi K, Takahashi H, Ohigashi H, Oshima K, Araki N, Nishiyama K, Ishikawa O. Risk factors for vertebral compression fractures in preoperative chemoradiotherapy with gemcitabine for pancreatic cancer. *Radiother Oncol* 2016;118:424–429
- (27) Otani K, Naito Y, Sakaguchi Y, Seo Y, Takahashi Y, Kikuta J, Ogawa K, Ishii M. Cell-cycle-controlled radiation therapy was effective for treating a murine malignant melanoma cell line in vitro and in vivo. *Sci Rep.* 2016;6:30689
- (28) Sasano T, Mabuchi S, Kuroda H, Takahashi R, Kozasa K, Isohashi F, Yoshioka Y, Ogawa K, Kimura T. Predictors of survival in patients with FIGO stage IVB cervical cancer. *Int J Gynecol Cancer* 2016;26:528–33
- (29) Seo Y, Tamari K, Yoshioka Y, Isohashi F, Suzuki O, Hayashi K, Takahashi Y, Baek S, Otani K, Ogawa K. Characterization of in vitro radiosensitization in mammalian cells using biomathematical modelling: implications for hypofractionated radiotherapy with a combined

- modality approach. Br J Radiol 2016;89:20150724
- (30) Sumida I, Yamaguchi H, Das IJ, Kizaki H, Aboshi K, Tsujii M, Yamada Y, Tamari K, Suzuki O, Seo Y, Isohashi F, Yoshioka Y, Ogawa K. Evaluation of the radiobiological gamma index with motion interplay in tangential IMRT breast treatment. J Radiat Res 2016;57:691–701
- (31) Sumida I, Shiomi H, Higashinaka N, Murashima Y, Miyamoto Y, Yamazaki H, Mabuchi N, Tsuda E, Ogawa K. Evaluation of tracking accuracy of the CyberKnife system using a webcam and printed calibrated grid. J Appl Clin Med Phys. 2016;17:5914
- (32) Sumida I, Yamaguchi H, Das IJ, Kizaki H, Aboshi K, Tsujii M, Yamada Y, Suzuki O, Seo Y, Isohashi F, Ogawa K. Intensity-modulated radiation therapy dose verification using fluence and portal imaging device. J Appl Clin Med Phys. 2016;17:5899
- (33) Sumita K, Harada H, Asakura H, Ogawa H, Onoe T, Murayama S, Nakamura S, Tanigawa N, Takahashi T, Nishimura T. Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study. Radiat Oncol. 2016;11:104–106
- (34) Suzuki G, Yamazaki H, Takenaka H, Aibe N, Masui K, Kimoto T, Tatekawa K, Nakashima A, Takenaka T, Asai J, Komori S, Wada M, Katoh N, Yamada K. Definitive Radiation Therapy for Angiosarcoma of the Face and Scalp. In Vivo. 2016;30:921–926
- (35) Tamura M, Ito Y, Sakurai H, Mizumoto M, Kamizawa S, Murayama S, Yamashita H, Takao S, Suzuki R, Shirato H. An Evaluation Method of Lifetime Attributable Risk for Comparing Between Proton Beam Therapy and Intensity Modulated X-Ray Therapy for Pediatric Cancer Patients by Averaging Four Dose-Response Models for Carcinoma Induction. Med Phys. 2016;43:3508.
- (36) Ueda Y., Oohira S., Isono M., Miyazaki M., Teshima T. Asymmetric margin setting at the cranial and caudal sides in respiratory gated and non-gated stereotactic body radiotherapy for lung cancer. BJR 2016;89: 20150499.
- (37) Uehara S, Oue T, Adachi K, Yoshioka Y, Nakahata K, Ueno T, Okuyama H. Tissue expander placement to prevent the adverse intestinal effects of radiotherapy in malignant pelvic tumors. J Pediatr Hematol Oncol 2016;38:e78–e81
- (38) Usami A, Kakimoto N, Aikawa T, Takahata S, Kishino M, Okahata R, Tsujimoto T, Uchiyama Y, Sasai T, Murakami S. The CT and MRI findings of fibrinous sialodochitis. M J Case. 2016;1: 019.1–4.
- (39) Yamaguchi H, Hori M, Suzuki O, Seo Y, Isohashi F, Yoshioka Y, Sumida I, Uemura M, Fujita K, Nagahara A, Ujike T, Kawashima A, Nonomura N, Tomiyama N, Ogawa K. Clinical significance of the apparent diffusion coefficient ratio in prostate cancer treatment with intensity-modulated radiotherapy. Anticancer Res 2016;36:6551–6556
- (40) Yamazaki H, Demizu Y, Okimoto T, Ogita M, Himei K, Nakamura S, Suzuki G, Yoshida K, Kotsuma T, Yoshioka Y. Comparison of re-irradiation outcomes for charged particle

- radiotherapy and robotic stereotactic radiotherapy using CyberKnife for recurrent head and neck cancers: A multi-institutional matched-cohort analysis. *Anticancer Res* 2016;36:5507-5514
- (41) Yamazaki H, Ogita M, Himei K, Nakamura S, Suzuki G, Yoshida K, Kotsuma T, Yoshioka Y. Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer. *J Radiat Res* 2016;57:288-93
- (42) Yamazaki H, Nakamura S, Suzuki G, Aibe N, Yoshida K. Superiority of charged particle therapy in treatment of hepatocellular carcinoma (Regarding Qi W.X. et al. charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis). *Radiother Oncol.* 2016;118:420
- (43) Yoshida K, Yamazaki H, Kotsuma T, Takenaka T, Ueda MM, Miyake S, Tsujimoto Y, Masui K, Yoshioka Y, Sumida I, Uesugi Y, Shimbo T, Yoshikawa N, Yoshioka H, Tanaka E, Narumi Y. Simulation analysis of optimized brachytherapy for uterine cervical cancer: Can we select the best brachytherapy modality depending on tumor size? *Brachytherapy* 2016;15:57-64
- (44) Yoshida K, Yamazaki H, Kotsuma T, Takenaka T, Ueda MM, Miyake S, Tsujimoto Y, Masui K, Yoshioka Y, Sumida I, Uesugi Y, Shimbo T, Yoshikawa N, Yoshioka H, Tanaka E, Narumi Y. Simulation analysis of optimized brachytherapy for uterine cervical cancer: Can we select the best brachytherapy modality depending on tumor size? *Brachytherapy* 2016;15:57-64
- (45) Yoshioka H, Shimbo T, Yoshida K, Yoshikawa N, Uesugi Y, Yamamoto K, Azuma H, Narumi Y. Treatment Results of Radiotherapy Combined with Balloon-occluded Arterial Infusion Chemotherapy for Invasive Bladder Cancer. *Anticancer Res* 36:731-6,2016
- (46) Yoshioka Y, Suzuki O, Isohashi F, Seo Y, Okubo H, Yamaguchi H, Oda M, Otani Y, Sumida I, Uemura M, Fujita K, Nagahara A, Ujike T, Kawashima A, Yoshida K, Yamazaki H, Nonomura N, Ogawa K. High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: Clinical results for a median 8-year follow-up. *Int J Radiat Oncol Biol Phys* 2016;94:675-82